Stock Events

Stock Events

Immunic 

$1.13
0
+$0.1+9.71% Today

Statistics

Day High
1.14
Day Low
1.13
52W High
-
52W Low
-
Volume
3,288
Avg. Volume
-
Mkt Cap
135.92M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-0.14
-0.12
-0.1
-0.08
Expected EPS
-0.084444
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-201.01MNet Income

Analyst Ratings

$5.33Average Price Target
The highest estimate is 7.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMUX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on discovering, developing, and delivering therapies for neurological diseases, similar to Immunic's focus on immune-mediated diseases.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is involved in the research and development of therapeutic treatments for a variety of diseases, including those in Immunic's target areas.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie operates in the same biopharmaceutical field, focusing on immunology and chronic diseases, competing directly with Immunic's product pipeline.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, including treatments for illnesses in areas that overlap with Immunic's research, such as inflammatory diseases.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb, having acquired Celgene, continues to be a competitor with a strong portfolio in immunology and oncology, areas relevant to Immunic.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals specializes in developing medications for autoimmune diseases and inflammatory conditions, directly competing with Immunic's therapeutic areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals engages in creating new therapies for treating cystic fibrosis and other serious diseases, competing for similar patient populations as Immunic.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that has a broad range of products competing across several of Immunic's key areas, including immunology.
Pfizer
PFE
Mkt Cap140.15B
Pfizer operates globally in various therapeutic areas, including inflammation and immunology, making it a competitor to Immunic in the biopharmaceutical sector.

About

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Show more...
CEO
ISIN
US4525EP1011

Listings

F
DE
10VA.F
XNAS
US
IMUX
BOATS
BOATS
IMUX.BOATS

0 Comments

Share your thoughts

FAQ

What is Immunic stock price today?▼
The current price of IMUX.BOATS is $1.13 USD — it has increased by +9.71% in the past 24 hours. Watch Immunic stock price performance more closely on the chart.
What is Immunic stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Immunic stocks are traded under the ticker IMUX.BOATS.
What is Immunic market cap?▼
Today Immunic has the market capitalization of 135.92M
When is the next Immunic earnings date?▼
Immunic is going to release the next earnings report on May 07, 2026.
What were Immunic earnings last quarter?▼
IMUX.BOATS earnings for the last quarter are -0.1 USD per share, whereas the estimation was -0.09 USD resulting in a -11.11% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Immunic revenue for the last year?▼
Immunic revenue for the last year amounts to 0 USD.
What is Immunic net income for the last year?▼
IMUX.BOATS net income for the last year is -201.01M USD.
When did Immunic complete a stock split?▼
Immunic has not had any recent stock splits.